No Covaxin stock in Delhi for any age group from Sunday: Atishi

"The Covishield stock for the 45-plus age group will last us 28 days," Atishi said.

Topics
Coronavirus | Coronavirus Tests | Coronavirus Vaccine

Press Trust of India  |  New Delhi 

Covaxin
Photo: Bloomberg

AAP MLA Atishi said on Friday that it has been 12 days since the stock of Covaxin was over for the 18-44 age group and now Delhi will run out of vaccine supply for the 45-plus category by Sunday.

During her daily vaccination bulletin, Atishi said that the Delhi government had about 10,000 Covaxin shots till Friday morning.

"We have about six lakh doses for the 45-plus group, majority of which are Covishield. We think most of the stock of 10,000 Covaxin shots must be over by today evening. We are estimating that most of our centres that were administering Covaxin will be shut from tomorrow," she said.

"And by the day after tomorrow (Sunday), Covaxin will not be available at any centre," the AAP MLA added.

According to official data released by the Delhi government, it had 11,290 Covaxin shots, 5,87,760 Covishield shots available for the 45-plus age group till Friday morning.

The national capital administered 53,018 vaccine doses on Thursday, out of which the first dose was given to 37,747 people and 15,271 people received the second dose.

"The Covishield stock for the 45-plus age group will last us 28 days," Atishi said.

She added that those who were administered the first dose of Covaxin a month ago will need the second dose in two weeks.

"It's an urgent requirement to replenish the stock of Covaxin in Delhi. We request the Centre to supply the vaccine. We will require as many Covaxin doses as we had a month before so we can vaccinate those who need it for the second dose," Atishi said.

"Delhi can't do with five lakh vaccines, we need 50 lakh vaccines in the month of June," she added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus
First Published: Fri, June 04 2021. 20:11 IST
RECOMMENDED FOR YOU